Physician profile
Ferdinand C Casis
NPI 1841209806
$285.12
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.97 · 2020: $18.24 · 2021: $95.54 · 2022: $88.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $44.52 | 2021-2022 | |
| Medtronic, INC. | $43.33 | 2022 | |
| Novo Nordisk INC | $34.72 | 2019-2021 | |
| Vistapharm, INC. | $28.54 | 2021 | |
| Antares Pharma, INC. | $23.80 | 2022 | |
| Shire North American Group INC | $18.29 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $18.24 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.79 | 2019 | |
| Radius Health, INC. | $16.49 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.04 | 2021 | |
| Medtronic Minimed, INC. | $13.33 | 2019 | |
| Dexcom, INC. | $12.03 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferdinand Casis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.